Eyewire News: The Podcast

Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava

Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Next-Generation FSYX Goggles Approved for Glaucoma

The FDA approves wireless pressure-modulating goggles for at-home glaucoma treatment; Bausch + Lomb launches a new PreserVision AREDS eye vitamin formation; and an Executive Strategic Advisor discusses the regulation environment for communication in eye care.  Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Future of Posterior Therapeutics

Leading ophthalmologists join us to discusses the hottest topics in the posterior segment treatment landscape.  Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Bayer Acquires Perfuse in $2.45 Billion Deal

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

How Ophthalmology Strategics are Rewriting the Playbook

Ophthalmic executives discuss strategies to scale and grow in today’s economic and regulatory environments.  Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]